INSERM leads in patent applications, reports European Patent Office
According to the European Patent Office (EPO), in 2019 the number of patents filed in the pharmaceutical and biotechnology sectors rose for a third consecutive year.
List view / Grid view
According to the European Patent Office (EPO), in 2019 the number of patents filed in the pharmaceutical and biotechnology sectors rose for a third consecutive year.
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
European Pharmaceutical Review explores how a surge in the number of warning letters for data integrity failings have prompted regulators to publish new guidelines.
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
Thermo Fisher Scientific Inc has announced that it is to acquire QIAGEN N V for a value of €39 per share at current exchange rates.
A study of over 602 brand-name prescription drugs shows that list prices increased over 1.5 times and net prices rose over 3.5 times inflation in the past decade.
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.
A report has revealed that the products in the pipeline to treat dry eye syndrome are expected to expand the number of options available for patients.
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
The drug’s developers reveal Keytruda increased progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) expressing PD-L1.
In a formal ceremony, the new headquarters for Novartis has been opened in White City, London, in close proximity to Imperial College London’s research campus.